Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments
Open Access
- 30 June 2013
- journal article
- other
- Published by Elsevier BV in Journal of Hepatology
- Vol. 58 (6), 1260-1262
- https://doi.org/10.1016/j.jhep.2013.01.021
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinomaJournal of Hepatology, 2012
- Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patientsHepatology, 2011
- Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with SunitinibClinical Cancer Research, 2011
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer, 2011
- Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlationJournal of Hepatology, 2011
- Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient CohortRadiology, 2010
- Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular CarcinomaJAMA, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term OutcomesGastroenterology, 2010